Discover Prostamax dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Prostamax is a Khavinson-family peptide bioregulator targeting prostate tissue, derived from the prostate-extract Cytomax peptide complex and studied in Russian clinical contexts for benign prostatic hyperplasia and chronic prostatitis. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when reconstituting Prostamax.
Prostamax is a short-peptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khatskelevich Khavinson as part of the broader Khavinson research program, with a specific organ-target framing: prostatic epithelium and supporting stromal tissue. Within the Khavinson framework — which proposes that organ-specific short oligopeptides exert tissue-targeted epigenetic regulation by binding gene-promoter regions in the same tissue from which they were originally derived — Prostamax sits as the synthetic peptide downstream of the multi-peptide prostate extract Prostatilen / Cytomax, the latter being the original cytomedine-class compound used in Russian urological clinical practice through the 1990s and 2000s for benign prostatic hyperplasia (BPH), chronic prostatitis, and post-surgical recovery.
Prostamax is a synthetic Ala-Glu-Asp-Gly (AEDG) tetrapeptide from the Khavinson program, sourced for prostate-tissue and aging research. It ships as a lyophilized powder, and because it shares the AEDG sequence with Epitalon, identity testing alone can't tell them apart — so the COA and fill accuracy matter most.
In the Khavinson framework, Prostamax is proposed to act through direct binding to gene-promoter DNA in prostatic epithelial and stromal cells, selectively modulating transcription of genes involved in androgen-receptor signalling, inflammation, and apoptosis regulation. This proposed direct-DNA-binding mechanism is unconventional and has not been independently characterised outside the Khavinson group.
Russian single-site studies have reported Prostamax (alongside the related preparation Prostatilen, a polypeptide prostatic extract) in benign prostatic hyperplasia and chronic prostatitis in elderly patients, with reported improvements in IPSS symptom scores, post-void residual volume, and prostatic-secretion markers versus standard care. These studies are not blinded or placebo-controlled, and no Western Phase 2 or 3 trial has been registered.
Prostamax has a reported half-life of ~30 min (short-peptide estimate), and the dose intervals researchers model most often fall around once daily (in 10–20 day courses). This Khavinson-type prostate bioregulator clears within an hour, so there is no systemic buildup; the effect is attributed to the course rather than a steady blood level. It is catalogued under Anti-Aging Peptides on WPA.
35 Prostamax reconstitution calculations have been logged by the WPA community. The most common dose entered is 750mcg (8 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 20mg (25 sessions). The most common dosing frequency is daily (7x/week) (4 logged protocols), followed by 5x/week (1).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.